Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S11 Ep20: Midweek Takeaway featuring Tim McCarthy, CEO of ImmuPharma #IMM

13:47
 
Share
 

Manage episode 521282490 series 3002024
Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. Tim explains why partnering discussions have attracted strong interest from multiple potential collaborators, including several top ten global pharma companies, and why the complexity and scale of that interest means a deal is now expected in 2026 rather than year-end 2025. He talks through what “finding the right partner” really looks like, how different deal structures might work (upfront payments, milestones, royalties), and why management remains very confident that a transformational licensing agreement will be secured despite the extended timeline.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
  continue reading

573 episodes

Artwork
iconShare
 
Manage episode 521282490 series 3002024
Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. Tim explains why partnering discussions have attracted strong interest from multiple potential collaborators, including several top ten global pharma companies, and why the complexity and scale of that interest means a deal is now expected in 2026 rather than year-end 2025. He talks through what “finding the right partner” really looks like, how different deal structures might work (upfront payments, milestones, royalties), and why management remains very confident that a transformational licensing agreement will be secured despite the extended timeline.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
  continue reading

573 episodes

Semua episod

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play